You have free access to this content

Cancer

Cover image for Vol. 120 Issue 14

15 July 2014

Volume 120, Issue 14

Pages 2069–2222

  1. Issue information

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Editorials
    5. Review Article
    6. Original Articles
    7. Errata
    1. You have free access to this content
      Issue information (pages i–viii)

      Version of Record online: 5 OCT 2015 | DOI: 10.1002/cncr.29710

  2. CancerScope

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Editorials
    5. Review Article
    6. Original Articles
    7. Errata
    1. You have free access to this content
    2. You have free access to this content
  3. Editorials

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Editorials
    5. Review Article
    6. Original Articles
    7. Errata
    1. You have free access to this content
      Cancer rehabilitation and prehabilitation may reduce disability and early retirement (pages 2072–2076)

      Julie K. Silver

      Version of Record online: 18 APR 2014 | DOI: 10.1002/cncr.28713

      Prehabilitation and rehabilitation are essential components of high-quality cancer care. Screening followed by evidence-based, interdisciplinary rehabilitation interventions improves physical and psychological health outcomes and will likely reduce work-related disability and the risk of early retirement in survivors.

    2. You have free access to this content
      Do patients with advanced cancer value the physical examination? (pages 2077–2079)

      Daniel P. Hunt

      Version of Record online: 4 JUN 2014 | DOI: 10.1002/cncr.28678

      Patients with advanced cancer still value the physical examination, according to the study by Kadakia et al. The exam serves both pragmatic and symbolic purposes for patients.

  4. Review Article

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Editorials
    5. Review Article
    6. Original Articles
    7. Errata
    1. You have free access to this content
      Magnetic resonance imaging in patients with newly diagnosed breast cancer: A review of the literature (pages 2080–2089)

      Melissa Pilewskie and Tari A. King

      Version of Record online: 18 APR 2014 | DOI: 10.1002/cncr.28700

      • image

      Data do not support the routine use of breast magnetic resonance imaging (MRI) in patients with newly diagnosed breast cancer. MRI is a useful adjunct in specific populations, such as women with occult primary breast cancer, or for assessing response to neoadjuvant chemotherapy.

  5. Original Articles

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Editorials
    5. Review Article
    6. Original Articles
    7. Errata
    1. Disease Site

      Chest and Lung Disease
      You have free access to this content
      Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations (pages 2090–2098)

      Youngjoo Lee, Geon Kook Lee, Yeon-Su Lee, Wenji Zhang, Jung-Ah Hwang, Byung-Ho Nam, Seok Hyun Kim, Joo-Hang Kim, Tak Yun, Ji-Youn Han, Heung Tae Kim and Jin Soo Lee

      Version of Record online: 15 APR 2014 | DOI: 10.1002/cncr.28711

      • image
      • image
      • image

      The presence of a preexisting T790M mutation is not a rare event in patients with epidermal growth factor receptor-mutant lung cancer and the frequency of the T790M mutation within a tumor has a critical impact on the tumor's biological characteristics and the clinical outcomes of therapy with epidermal growth factor receptor tyrosine kinase inhibitors.

    2. Gastrointestinal Disease
      You have free access to this content
      Patterns of recurrence after trimodality therapy for esophageal cancer (pages 2099–2105)

      Jennifer A. Dorth, John A. Pura, Manisha Palta, Christopher G. Willett, Hope E. Uronis, Thomas A. D'Amico and Brian G. Czito

      Version of Record online: 7 APR 2014 | DOI: 10.1002/cncr.28703

      • image
      • image
      • image

      To the authors' knowledge, there is no consensus as to which regional lymph nodes should be targeted with radiation among patients with esophageal cancer, and patterns of failure are poorly defined. In the current series, 2-year rates of lymph node failure (NF) and isolated NF were 14% and 3%, respectively.

    3. You have free access to this content
      Colorectal cancer screening in high-risk groups is increasing, although current smokers fall behind (pages 2106–2113)

      Aminat O. Oluyemi, Amy R. Welch, Lisa J. Yoo, Erik B. Lehman, Thomas J. McGarrity and Cynthia H. Chuang

      Version of Record online: 15 APR 2014 | DOI: 10.1002/cncr.28707

      • image
      • image
      • image
      • image

      Recently identified high-risk groups for colorectal cancer include the black, obese, diabetic, and smoking populations. The prevalence of colorectal cancer screening is increasing in all high-risk groups; however, current smokers have lower screening odds, which identifies them as a target group for intensified screening efforts.

    4. Genitourinary Disease
      You have free access to this content
      The rise and fall of prostate brachytherapy: Use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base (pages 2114–2121)

      Jeffrey M. Martin, Elizabeth A. Handorf, Alexander Kutikov, Robert G. Uzzo, Justin E. Bekelman, Eric M. Horwitz and Marc C. Smaldone

      Version of Record online: 15 APR 2014 | DOI: 10.1002/cncr.28697

      • image
      • image
      • image

      Brachytherapy has been shown to be an efficacious and cost-effective treatment among patients with localized prostate cancer. For patients with localized prostate cancer treated at National Cancer Data Base institutions, there has been a steady decline in brachytherapy use since 2003, which may have significant health policy implications.

    5. Hematologic Malignancies
      You have free access to this content
      Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission (pages 2122–2129)

      Sai Ravi Pingali, Sarah W. Jewell, Luiza Havlat, Martin A. Bast, Jonathan R. Thompson, Daniel C. Eastwood, Nancy L. Bartlett, James O. Armitage, Nina D. Wagner-Johnston, Julie M. Vose and Timothy S. Fenske

      Version of Record online: 7 APR 2014 | DOI: 10.1002/cncr.28698

      • image
      • image
      • image

      Clinical surveillance is not inferior to routine surveillance imaging for patients with classical Hodgkin lymphoma who achieve complete remission with frontline therapy. Routine surveillance imaging is associated with significantly increased estimated imaging charges.

    6. You have full text access to this OnlineOpen article
      Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD–negative acute myeloid leukemia (pages 2130–2141)

      Shuang Qu, Bin Liu, Xiaoling Guo, Hongshun Shi, Meifeng Zhou, Li Li, Shulan Yang, Xiuzhen Tong and Haihe Wang

      Version of Record online: 15 APR 2014 | DOI: 10.1002/cncr.28668

      • image
      • image
      • image
      • image
      • image
      • image

      FLT3-ITD–negative acute myeloid leukemia (AML) accounts for up to approximately 70% to 80% of all cases. This study demonstrates that PRL-3, an independent driver in FLT3-ITD–negative AML, is adversely correlated to patient survival. Mechanistically, PRL-3 can promote AML cell cycle progression and render antiapoptosis features to AML cells, suggesting it could be an independent factor for AML diagnosis and therapy.

    7. You have free access to this content
      Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations (pages 2142–2149)

      Yesid Alvarado, Hagop M. Kantarjian, Rajyalakshmi Luthra, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia-Manero, Marina Konopleva, Zeev Estrov, Michael Andreeff and Jorge E. Cortes

      Version of Record online: 15 APR 2014 | DOI: 10.1002/cncr.28705

      • image

      Secondary FLT3-tyrosine kinase domain mutations can arise after treatment with FLT3 inhibitors in patients with FLT3-internal tandem duplication–mutated acute myeloid leukemia. D835/I836 mutations were observed in at least 20% of patients after treatment, and are associated with resistance and poor prognosis.

    8. Hepatobiliary Disease
      You have free access to this content
      Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use (pages 2150–2157)

      Edoardo G. Giannini, Giorgio Sammito, Fabio Farinati, Francesca Ciccarese, Anna Pecorelli, Gian Lodovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Franco Borzio, Giuseppe Cabibbo, Martina Felder, Antonio Gasbarrini, Rodolfo Sacco, Francesco Giuseppe Foschi, Gabriele Missale, Filomena Morisco, Gianluca Svegliati Baroni, Roberto Virdone, Franco Trevisani and for the Italian Liver Cancer (ITA.LI.CA) Group

      Version of Record online: 10 APR 2014 | DOI: 10.1002/cncr.28706

      • image

      In patients with hepatocellular carcinoma, serum levels of α-fetoprotein are influenced by sex, characteristics of chronic liver disease, and features of tumor aggressiveness. These findings confirm the limits of using α-fetoprotein as a clinical aid in patients with known or suspected hepatocellular carcinoma.

    9. Melanoma
      You have free access to this content
      Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients (pages 2158–2163)

      Vincent Launay-Vacher, Sarah Zimner-Rapuch, Nicolas Poulalhon, Thibault Fraisse, Valérie Garrigue, Morgane Gosselin, Sabine Amet, Nicolas Janus and Gilbert Deray

      Version of Record online: 15 APR 2014 | DOI: 10.1002/cncr.28709

      Several cases of vemurafenib renal toxicity have been reported in the literature, whereas nephrotoxicity did not appear as a potential side effect of therapy in clinical development of the drug. This is the first case series reporting several cases, with analysis of data available so far, on how such a toxicity may occur.

    10. Discipline

      Clinical Trials
      You have free access to this content
      Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors (pages 2164–2173)

      David S. Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Siqing Fu, Stacy L. Moulder, Sarina Piha-Paul, Apostolia M. Tsimberidou, YueJin Wen, Kirk S. Culotta, Kenna Anderes, Darren W. Davis, Wen Liu, Goldy C. George, Luis H. Camacho, Susan Percy Ivy and Razelle Kurzrock

      Version of Record online: 17 APR 2014 | DOI: 10.1002/cncr.28701

      • image
      • image
      • image

      Targeting angiogenesis and disrupting the cross-talk between stroma and cancer cells is a promising strategy for cancer treatment. Vascular endothelial growth factor is critical in orchestrating neoangiogenesis. The current study was conducted to evaluate the safety and biological activity of the dual inhibition of the vascular endothelial growth factor pathway with combined bevacizumab and cediranib.

    11. Disparities Research
      You have free access to this content
      Racial differences in physical activity among breast cancer survivors: Implications for breast cancer care (pages 2174–2182)

      Brionna Y. Hair, Sandi Hayes, Chiu-Kit Tse, Mary Beth Bell and Andrew F. Olshan

      Version of Record online: 9 JUN 2014 | DOI: 10.1002/cncr.28630

      Physical activity after breast cancer diagnosis is associated with improved survival. The results of the current study suggest that more efforts should be made to encourage physical activity in patients with breast cancer, and especially among African American women.

    12. You have free access to this content
      Guideline-concordant cancer care and survival among American Indian/Alaskan Native patients (pages 2183–2190)

      Sara H. Javid, Thomas K. Varghese, Arden M. Morris, Michael P. Porter, Hao He, Dedra Buchwald, David R. Flum and for the Collaborative to Improve Native Cancer Outcomes (CINCO)

      Version of Record online: 7 APR 2014 | DOI: 10.1002/cncr.28683

      • image
      • image

      Fewer American Indian/Alaskan Native patients than white patients receive guideline-concordant cancer treatment for the 4 most common cancers (breast, colon, prostate, and lung). Nonreceipt of guideline-concordant treatment is associated with worse survival; however, when such treatment is received, the disease-specific survival of American Indians/Alaskan Natives and whites does not differ significantly.

    13. Epidemiology
      You have full text access to this OnlineOpen article
      The relationship between area poverty rate and site-specific cancer incidence in the United States (pages 2191–2198)

      Francis P. Boscoe, Christopher J. Johnson, Recinda L. Sherman, David G. Stinchcomb, Ge Lin and Kevin A. Henry

      Version of Record online: 27 MAY 2014 | DOI: 10.1002/cncr.28632

      • image
      • image

      A majority of cancer sites exhibit significant associations with area poverty rates. Those associated with higher poverty had lower incidence but higher mortality than those associated with lower poverty.

    14. Psychosocial Oncology
      You have free access to this content
      Early retirement in cancer patients with or without comorbid mental health conditions: A prospective cohort study (pages 2199–2206)

      Susanne Singer, Alexandra Meyer, Sabine Wienholz, Susanne Briest, Anna Brown, Andreas Dietz, Harald Binder, Sven Jonas, Kirsten Papsdorf, Jens-Uwe Stolzenburg, Uwe Köhler, Jörg Raßler, Rüdiger Zwerenz, Katharina Schröter, Anja Mehnert, Margrit Löbner, Hans-Helmut König and Steffi G. Riedel-Heller

      Version of Record online: 18 APR 2014 | DOI: 10.1002/cncr.28716

      Mental health conditions are risk factors for early retirement in cancer patients. This effect differs according to the type of mental disorder and the patient's income level.

    15. Supportive Care
      You have free access to this content
      Phase angle for prognostication of survival in patients with advanced cancer: Preliminary findings (pages 2207–2214)

      David Hui, Swati Bansal, Margarita Morgado, Rony Dev, Gary Chisholm and Eduardo Bruera

      Version of Record online: 4 JUN 2014 | DOI: 10.1002/cncr.28624

      • image
      • image

      In this prospective study, the authors found that phase angle was a novel predictor of poor survival, independent of established prognostic factors, in the advanced cancer setting. This objective and noninvasive tool may be useful for bedside prognostication.

    16. You have free access to this content
      Cancer patients' perceptions regarding the value of the physical examination: A survey study (pages 2215–2221)

      Kunal C. Kadakia, David Hui, Gary B. Chisholm, Susan E. Frisbee-Hume, Janet L. Williams and Eduardo Bruera

      Version of Record online: 4 JUN 2014 | DOI: 10.1002/cncr.28680

      • image

      There are no studies on how patients with advanced cancer perceive being routinely examined. Beyond diagnostic utility, the physical examination appears to have symbolic significance and should not be minimized in patients with advanced cancer.

  6. Errata

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Editorials
    5. Review Article
    6. Original Articles
    7. Errata
    1. You have free access to this content
    2. You have free access to this content

SEARCH

SEARCH BY CITATION